On November 11, WUXI BIO fell 3.43% in Regular Trading, trading at HK$48.04, with turnover of HK$311 million.
Recent public information indicates the company’s previously disclosed catalysts remain the long-term Fresenius biosimilars collaboration and supportive broker expectations, but those positives had already been repeatedly traded in prior sessions, while the latest pullback was more closely associated with broader weakness across related names.
Background context shows WUXI BIO previously entered a 10-year exclusive development agreement covering up to 37 biosimilar candidates with Fresenius, described as the largest such development deal announced in the biosimilars industry, tied to originator drugs with combined annual list-price sales of more than EUR370 billion. Separately, Citi placed the company on a 90-day positive catalyst watchlist, citing potential for a fourth-quarter overall guidance raise, while UBS maintained a Buy rating with a HK$62 target price.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments